Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor

(MedPage Today) -- SAN DIEGO -- Pirtobrutinib (Jaypirca) delayed disease progression versus other available options in patients with chronic lymphocytic leukemia (CLL) who had previously received a covalent Bruton's tyrosine kinase (BTK) inhibitor...